KYNTRA BIO, INC. Long-term Debt, Gross
KYNTRA BIO, INC. (KYNB) had Long-term Debt, Gross of $74.10 million as of 2023-05-31, per its 10-K filed 2025-03-17.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentCarryingAmount · last filed 2025-03-17
- 2023-05-31: Long-term Debt, Gross $74.10M.
- 2023-05-08: Long-term Debt, Gross $74.10M.
| Period end | Long-term Debt, Gross |
|---|---|
| 2023-05-31 | $74.10M 10-K · filed 2025-03-17 |
| 2023-05-08 | $74.10M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |